Hematology

Novel method may reduce the length of treatment time and decrease side effects.

Top cancer-related news from the past week.

Research offers enhanced method to assess effects of cancer drugs on normal and healthy cells.

Excessive out-of-pocket costs can become an adverse event from treatment.

More than just biological factors can affect patient outcomes.

Expansion covers patients who have greater than 30% myeloblasts.

Kyprolis is for injection in patients with relapsed multiple myeloma.

Average reimbursement for Part B oncology drugs is 52% higher in 340B hospitals than in community cancer clinics.

Chronic lymphocytic leukemia treatment reprograms T cells to hunt and kill cancer cells.

Research will lead to novel viral and immunologic treatments.

Combination of immunotherapy and aspirin showed a substantial decrease in bowel and melanoma skin cancer growth in mice.

Treatment removes a tumor's defenses.

Chemotherapy drugs can convert gastrointestinal bacteria into toxic species that causes severe diarrhea.

Clinical outcomes expected to continue improving as new treatments arrive.

New approach may combine with existing medications to improve survival.

Ixazomib is the first investigational oral proteasome inhibitor for relapsed and/or refractory multiple myeloma.

Daratumumab monotherapy slows disease progression a year after treatment.

Researchers examine how a cell distinguishes between damaged DNA and foreign viral DNA.

Genetic profiling after initial chemotherapy may help oncologists predict early prognosis.

Daratumumab causes the targeted killing of CD38-carrying tumor cells.

Vaccine primes immune cells to attack patient-specific tumor tissue.

The latest news in oncology treatment research.

Varubi prevents nausea and vomiting associated with vomit-inducing cancer chemotherapy.

Oncologists will now be able to measure progress in cancer treatments.

Elotuzumab is an immunostimulatory antibody combination therapy for patients who received one or more prior therapies.